RSPI (RespireRx Pharmaceuticals) Shares Outstanding (EOP): 298.33 Mil (As of Sep. 2023)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Shares Outstanding (EOP)?

RespireRx Pharmaceuticals RSPI 12 Shares Outstanding (EOP) is 298.33 Mil as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. RespireRx Pharmaceuticals's shares outstanding for the quarter that ended in Sep. 2023 was 298.33 Mil.

RespireRx Pharmaceuticals's quarterly shares outstanding increased from Jun. 2023 (220.73 Mil) to Sep. 2023 (298.33 Mil). It means RespireRx Pharmaceuticals issued new shares from Jun. 2023 to Sep. 2023 .

RespireRx Pharmaceuticals's annual shares outstanding increased from Dec. 2021 (97.89 Mil) to Dec. 2022 (125.54 Mil). It means RespireRx Pharmaceuticals issued new shares from Dec. 2021 to Dec. 2022 .


RespireRx Pharmaceuticals  (OTCPK:RSPI) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


RespireRx Pharmaceuticals Shares Outstanding (EOP) Related Terms


RespireRx Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Shares Outstanding (EOP) Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.42 71.27 97.89 125.54

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.59 125.54 144.33 220.73 298.33

RSPI vs CNBX, NAVB, IPIX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Shares Outstanding (EOP) falls into.


RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 298.33 Mil mean?
RespireRx Pharmaceuticals (RSPI) has a Shares Outstanding (EOP) of 298.33 Mil as of Sep. 2023. The total shares a company has outstanding, at period-end. View historical data on RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Shares Outstanding (EOP) too high?
RespireRx Pharmaceuticals' current Shares Outstanding (EOP) is 298.33 Mil. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Shares Outstanding (EOP) compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Shares Outstanding (EOP) of 298.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Shares Outstanding (EOP) is 298.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Shares Outstanding (EOP) of 298.33 Mil. The current Shares Outstanding (EOP) is 298.33 Mil. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Shares Outstanding (EOP) is 298.33 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price